Non-myeloablative allogeneic transplantation
Author(s)
Bibliographic Information
Non-myeloablative allogeneic transplantation
(Cancer treatment and research)
Kluwer Academic Publishers, c2002
Available at 3 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references and index
Description and Table of Contents
Description
Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem cells and lymphocytes. It has the potential to deliver the potent anti-tumor immunotherapy and bone marrow replacement capacity of allogeneic stem cell transplantation to patients with reduced treatment-related morbidity and mortality. It may also enable allogeneic transplantation in patients who would be considered ineligible for conventional transplants because of co-morbidity or advanced age. However, this approach may necessitate more careful monitoring of post-transplant chimerism and malignant disease-status than is usual with conventional allografting. There is also controversy regarding the best preparative regimen and graft-versus-host disease prophylaxis to use.
Table of Contents
- Contributors. Preface. 1. Development of allogeneic hematopoietic stem cell transplantation (HSCT)
- J. Castro, E.D. Ball. 2. Immunosuppression with limited toxicity: characteristics of nucleoside analogs and anti-lymphocyte antibodies used in non-myeloablative hematopoietic cell transplantation
- A. Bashey. 3. Mobilization of allogeneic peripheral blood progenitor cells
- P. Law, T. Lane. 4. Non-myeloblative induction of mixed hematopoietic chimerism: application to transplantation tolerance and hematologic malignancies in experimental and clinical studies
- M. Sykes, T. Spitzer. 5. Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer
- A.M. Carella, E. Lerma, M. Cavaliere, M.T. Corsetti. 6. Non-myeloablative hematopoietic stem cell transplantation (NHT) in the treatment of human malignancies: from animal models to clinical practice
- A. Shimoni, A. Nagler. 7. Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy
- I. Khouri, S. Giralt, R. Champlin. 8. Outpatient allografting in hematologic malignancies and nonmalignant disorders - applying lessons learned in the canine model to humans
- M. Maris, R.F. Storb. 9. Non-myeloablative transplants for congenital diseases
- J. Donahue, E. Carrier. Index.
by "Nielsen BookData"